In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Solvay Pharmaceuticals acquires NeoPharma

Executive Summary

In a move that strengthens its position in CNS diseases and Parkinson's disease (PD) in particular, Solvay Pharmaceuticals is acquiring all the 3.3mm shares (fully diluted) of the Swedish pharmaceutical company NeoPharma AB (drugs and delivery systems focusing on PD) via a friendly tender offer. The purchase price is SEK640mm ($91.7mm) in cash or about 22 times NeoPharma's sales for the 12 months ended June 2004.
Deal Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Drug Delivery
  • Medical Devices
    • Implantable Devices
    • Infusion Therapy Equipment and Supplies
Deal Status
  • Final
Deal Type
  • Acquisition
    • Full Acquisition
    • Payment Includes Cash

Related Companies